Immunohelix Co., Ltd, one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem
Immunohelix Co.Ltd., one of our portfolio companies in Japan, was selected as one of the supported projects in "Strengthening Program for Pharmaceutical Venture Ecosystem in 2022” by Japan Agency for Medical Research and Development (AMED).
In this program, AMED provides matching financial supports for the drug development of selected projects on condition that an equity investment is executed by an AMED certified venture capital firm that provides hands-on support focusing on drug discovery and development.
Immunohelix Co., Ltd. is a private biotech company whose platform technology is immune cell-specific delivery system using Schizophyllan. As one of the pipelines, the company will develop a novel vaccine against Respiratory syncytial virus, using the company’s proprietary pDC-targeting TLR9 agonist as an adjuvant and a novel antigen.
For more detailed information please visit the above AMED web pages.